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Abstract
Purpose: Development of tumor-specific therapies for the treatment of recalcitrant non-small 
cell lung cancers (NSCLCs) are urgently needed. Here, we investigated the ability of ß-lapachone 
(ß-lap, ARQ761 in clinical form) to selectively potentiate the effects of ionizing radiation (IR, 1–3 
Gy) in NSCLCs that over-express NAD(P)H:Quinone Oxidoreductase 1 (NQO1).
Experimental Design: The mechanism of lethality of low dose IR in combination with 
sublethal doses of ß-lap were evaluated in NSCLC lines in vitro and validated in subcutaneous and 
orthotopic xenograph models in vivo. Pharmacokinetics and pharmacodynamics (PK/PD) studies 
comparing single versus co-treatments were performed to validate therapeutic efficacy and 
mechanism of action.
Results: ß-Lap administration after IR treatment hyperactivated PARP, greatly lowered NAD
+/ATP levels, and increased DSB lesions over time in vitro. Radiosensitization of orthotopic, as 
well as subcutaneous, NSCLCs occurred with high apparent cures (>70%), even though 1/8 ß-lap 
doses reach subcutaneous versus orthotopic tumors. No methemoglobinemia or long-term 
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toxicities were noted in any normal tissues, including mouse liver that expresses the highest level 
of NQO1 (~12 Units) of any normal tissue. PK/PD responses confirm that IR + ß-lap treatments 
hyperactivate PARP activity, greatly lower NAD+/ATP levels and dramatically inhibit DSB repair 
in exposed NQO1+ cancer tissue, while low NQO1 levels and high levels of Catalase in associated 
normal tissue were protective.
Conclusion: Our data suggest that combination of sublethal doses of ß-lap and IR is a viable 
approach to selectively treat NQO1-overexpressing NSCLC and warrant a clinical trial using low-
dose IR + ß-lapachone against patients with NQO1+ NSCLCs.
STATEMENT OF TRANSLATIONAL RELEVANCE
Lung cancer remains the leading cause of cancer-related death in men and women in North 
America. Patients diagnosed with non-small cell lung cancer (NSCLC) have few effective 
treatment options, which cause undesirable side-effects due to lack of tumor selectivity when used 
at higher doses. There is an urgent need for personalized strategies to selectively target cancer 
while sparing normal tissue. This study delineates the mechanistic basis for tumor-selective 
potentiation of ionizing radiation (IR) in combination with β-lapachone (β-lap, ARQ761 in 
clinical form), an NQO1-bioactivatable agent that induces lethal DNA damage in recalcitrant 
NSCLCs (~90% overexpress NQO1 as a biomarker). Non-toxic doses of β-lap can be combined 
after treatment with IR to selectively and synergistically kill NSCLCs with no apparent normal 
tissue toxicity in vivo. Our findings warrant a clinical trial to combine sublethal doses of IR + ß-
lap against patients with NQO1(+) NSCLCs for precision-guided medicine.
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INTRODUCTION
We previously demonstrated that ß-lap was a unique substrate for NAD(P)H:Quinone 
Oxidoreductase 1 (NQO1) (E.C.1.6.5.2 ) (1–10), wherein the enzyme performs a futile two-
electron oxidoreduction of the compound using NAD(P)H to generate an unstable 
hydroquinone form of ß-lap (7,10,11). Unique to this quinone, its hydroquinone form is 
highly unstable and spontaneously undergoes two oxidoreductive back-reactions to its 
original drug form (1,3–7,10–15). NQO1 thereby constantly undergoes a futile redox cycle 
using NAD(P)H and creating two moles of superoxide in the two-step back-reaction (6,7). A 
tremendous pool of NAD(P)+ forms (4,6–9,12,16,17), along with very high levels of 
superoxide, which are rapidly converted to hydrogen peroxide (H2O2). High doses of H2O2 
eventually damages the DNA of NQO1+ cancer cells (15,18,19). The reaction can also cause 
a strong lethal effect in adjacent NQO1Low cancer cells in the same tumor via an H2O2-
dependent bystander effect mediated by low catalase levels in these cancers (15). AP 
(apurinic, apyrimidinic, or abasic) sites, DNA single strand breaks (SSBs) and DNA double 
strand breaks (DSBs) form in NQO1+ cancer cells exposed to ß-lap via a strong PARP1 
hyperactivation (6,7,12,16), which then degrades the heightened NAD+ levels resulting from 
NQO1-dependent redox cycling of this unique quinone (3,4,7,10,15,20). This process is 
mediated by H2O2-induced release of calcium from endoplasmic reticulum (ER) stores 
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(12,16). Delineating the mechanism of action of ß-lap has revealed exciting synergistic 
combinations, for example, using glutamate synthase inhibitors (BEPTES, CB089) (18), 
DNA base excision repair inhibitors (methoxyamine and XRCC1 depletion) (19), as well as 
PARP inhibitors (10). Analyses of numerous NQO1-expressing breast, prostate, lung, 
pancreatic and head and neck cancer cells shows that ß-lapachone (a prototypic NQO1 
bioactivatable drug) kills cancer cells by an NQO1-dependent ischemia-reperfusion 
mechanism independent of oncogenic driver or passenger statuses, regardless of p53 or cell 
cycle status, and independent of over-expressed anti-apoptotic mechanisms (e.g., Bcl2, Bax 
loss) that may drive resistance (10).
We previously exploited ß-lapachone as a radiosensitizer of cancer cells in vitro, initially 
without knowing the mechanism by which synergistic killing with IR occurred (21,22). 
After determining the mechanism of action of ß-lap, we then used NQO1 over-expressing 
human prostate or head and neck cancer xenograft mouse models to show how the 
compound radiosensitized human cancers in vivo (11,23). Our data showed that synergy 
could be accomplished using IR + ß-lap via creation of normal, rapidly repaired DNA 
lesions that simultaneously hyperactive PARP1, where IR or drug alone did not separately 
meet the DNA damage required. Here, we demonstrate that ß-lap suppresses IR-induced 
DSB repair and we illustrate the efficacy of IR + ß-lap treatments against non-small cell lung 
cancers (NSCLCs) that commonly have significantly elevated levels of NQO1, but 
concomitantly low Catalase (Cat) levels (10). We also tested the hypotheses that massive 
PARP1 hyperactivation reactions after IR + ß-lap led to dramatic accompanying NAD+/ATP 
losses that ultimately inhibit DSB repair processes (initiated by IR exposure) and may lead 
to NQO1-dependent NAD+-Keresis cell death (14) responses specific for NQO1+ NSCLC 
tumors. No methemoglobinemia or toxicities to normal tissues were found in IR + ß-lap-
exposed mice. Data presented in this study warrants a clinical trial using low-dose 
radiotherapy with the clinically available NQO1 bioactivatable drug (ARQ761) against 
NSCLCs containing wild-type NQO1 as a biomarker for personalized medicine.
MATERIALS AND METHODS
Reagents and chemicals.
β-Lapachone (ß-lap) was synthesized and purified by us (6). Dicoumarol (DIC), hydrogen 
peroxide (H2O2), Hoechst 33342, bovine serum albumin, and cytochrome c were purchased 
from Sigma-Aldrich (St. Louis, MO). HPβCD (>98% purity) was purchased from 
Cyclodextrin Technologies Development, Inc. (High Springs, FL) and β-lap-HPβCD was 
prepared as described (24).
NQO1 enzyme assays.
NQO1 enzyme activities from cancer cells or tumor or normal tissues were measured as 
dicoumarol-inhibited units either with or without cytochrome C (1,25).
Cell lines and tissue culture.
Human nonsmall cell lung cancer (NSCLC) cells were generated by the UTSW-MD 
Anderson SPORE in lung cancer (26) or other cells were purchased (Lewis lung carcinoma, 
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A549) from the American Tissue Culture Collection (Manassas, VA). Cells were grown as 
described (10) and routinely screened free of mycoplasma.
Cell culture irradiations and colony forming ability assays.
All cell culture irradiations were performed using a Mark 1 irradiator with a 137Cesium 
source delivering a dose rate of 3.49 Gy/minute (JL Shepherd & Associates, San Fernando, 
CA). Varying doses of β-lap dissolved in DMSO (± Dicoumarol) were added immediately 
after irradiation and incubated with the drug for two hours in a humidified incubator (37 °C, 
5% CO2). After two-hour treatment, media was replaced with fresh complete media and 
allowed to grow for several doubling periods. Colony forming ability assays were performed 
using 500–15,000 cells per 100 mm plates as described (21,22). Colonies of >100 healthy 
normal-appearing cells were counted and normalized to vehicle-treated control cells.
Antibodies.
Antibodies used for immunofluorescence and Western blotting, included: NQO1 (A180), 
PARP1 (SC-8007, Santa Cruz, La Jolla, CA), ß-actin (C4, Santa Cruz), PAR (Trevigen, 
Gaithersburg, MD), 53BP1 (Santa Cruz), γ-H2AX (JBW301, Millipore, Temecula, CA), 
phosphorylated ATM (p-ATM-s1981), total-ATM (t-ATM) and α-tubulin (Santa Cruz).
Western blot assessments.
Westerns were performed using ECL chemiluminescent detection and density analyses using 
NIH ImageJ with intensity normalization (6,7,10,25).
DSB detection and repair.
Cells were imaged by immunofluorescence using Leica DM5500 fluorescent microscopy for 
a marker of DSB formation. The number of 53BP1 foci in a given cell nucleus was 
quantified and graphed as percent (%) nuclei with ≥10 53BP1 foci/nucleus (6,7,25). 
Alternatively, for assessments in vivo, γ-H2AX levels were screened and quantified by 
Western blotting (10).
Tumor irradiations and antitumor activity assays.
Luciferase-labeled tumors (LLC-luc or NSCLC-luc) were generated by injecting 5 × 106 
tumor cells into the subcutaneous space on the backs, or into tail veins to generate orthotopic 
xenografts, of female athymic nude mice or NSG mice weighing 18–20 grams obtained from 
the UT Southwestern institutional breeding core. In general, survival and tumor volume data 
were graphed from two separate studies, each with 10 combined mice/group. 
Bioluminescence imaging (BLI), antitumor activity, and survival studies using subcutaneous 
(300 mm3) or orthotopic NSCLC (A549) xenograft-bearing athymic nude or NSG mice 
were performed. Subcutaneous Lewis lung carcinoma (LLC) tumors (200 mm3) were raised 
in a same manner. Four weeks after implantation, mice were treated with or without various 
doses of IR (Gy), using specific collimators for delivery only to the lung or subcutaneous 
tumor flank areas every other day for five treatments. Immediately following IR treatments, 
mice were then exposed iv with or without HPβCD or sub-lethal doses of β-lap-HPβCD by 
tail vein injection (9). Animals were irradiated using an X-RAD 320 small animal irradiator 
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(Precision X-Ray, North Branford, CT). For combination IR + β-lap-HPβCD treatments, β-
lap-HPβCD was administered within 30 min post-IR. Tumor volumes were either directly 
measured using calipers (for subcutaneous models) and/or using Bioluminescence (BLI)-
based tumor volume estimates for orthotopic models (7,10). Long-term survival and target 
validation assays were performed with log-rank tests for survival (7,9,10). All animal studies 
were carried out under a University of Texas at Southwestern Medical Center Institutional 
Animal Care and Use Committee (IACUC) approved protocol and in accordance with the 
guidelines for ethical conduct in the care and use of animals in research.
Biomarker and pharmacokinetic analyses (PK/PD).
Pharmacokinetics (PK) of β-lap levels in blood, tumor and normal tissues were assessed by 
LC-MS/MS analyses following extraction of plasma, tumor or normal tissue homogenates 
with acetonitrile (7,9,10,27). An unpaired t-test (GraphPad QuickCalcs, San Diego, CA) was 
used to evaluate significant differences in β-lap concentrations after different treatments. 
Pharmacodynamic (PD) parameters of PAR formation and γH2AX in normal tissue and 
tumors were simultaneously performed using pooled samples from three animals per time 
point (7,10,27). Please refer to the Supplementary Information for a more detailed 
description of the ATP, NAD+/NADH quantification in tumor lysates at indicated treatment 
conditions.
Statistical Analysis.
Data (means, ± standard deviations) were graphed and ANOVA used to compare groups. 
Two-tailed Student’s t-tests for independent measures with Holm-Sidak correction for 
multiple comparisons, if >1 comparisons, were performed. Minimum replicate size for any 
experiment was n=3. Alpha was set to 0.05. Curve fitting and calculation of LD50 values, 
ANOVA, and two-tailed Student t-tests for statistical significance were performed in 
GraphPad Prism 6.0. Images were representative of experiments or stainings repeated three 
times. *p<0.05; **p<0.01; ***p<0.001; and ****p<0.0001.
Synergy Calculations.
Synergy interactions between two drugs were evaluated as previously described (10) using 
two methods: 1) Direct comparisons made between the effect of combined treatments and 
the effect of individual drugs in each experiment; and 2) Formal synergy effects evaluations 
used a strict method proposed by Chou and Talalay (28) and Lee et al., (29) where pooled, 
multiple dose-responses for each of the treatments were required.
RESULTS
ß-Lapachone (ß-lap) exerts NQO1-dependent radiosensitization of NSCLC cells.
A549 NSCLC cells express high levels of NQO1 typical of most NSCLC tumors, with 
relatively low expression of catalase, so they are a good representative cell line model to use 
(10). A549 cells are hypersensitive to ß-lap, where inhibiting NQO1 activity with 
dicoumarol greatly suppressed lethality (Fig. 1A). A striking dose-response with NQO1+ 
cells is noted, where 3 µM ß-lap (2 h) results in cell stress with minimal lethality (~80% 
survival) and 4 µM (2 h) causes significant cell death (>LD50) as previously demonstrated to 
Motea et al. Page 5
Clin Cancer Res. Author manuscript; available in PMC 2020 April 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
be through programmed necrosis (10). Irradiation of A549 cells with lower doses of IR (1–3 
Gy) and then exposing cells immediately thereafter with sublethal doses of ß-lap (1–3 µM, 
Fig. 1A) resulted in significant dose-response increases in lethality (Fig. 1B). 
Radiosensitization was also noted when cells were exposed to higher IR doses (>3 Gy) in 
combination with lower concentrations (<LD50) of ß-lap (1–3 µM) (Fig. 1B). Administration 
of dicoumarol (DIC), a well-utilized NQO1 inhibitor (10), prevented lethality of irradiated 
(2–7 Gy) A549 cells co-treated with ß-lap (3 µM). Similarly, H1650 NSCLC cells exposed 
to IR (2 Gy) and then treated immediately with various concentrations of ß-lap (1–5 µM) for 
2 h post-irradiation, exhibited significant synergistic responses compared to 2 Gy IR dose 
alone, or to various low doses of ß-lap alone (Fig. 1C). Radiosensitization of IR + ß-lap was 
prevented by inhibiting NQO1 via co-administration of 50 µM dicoumarol immediately 
following IR (Fig. 1C), suggesting NQO1-dependent lethal effects. H1650 cells express 
~100 units of NQO1, which is sufficient to induce a synergistic effect. As previously 
reported (21,22), adding low doses of ß-lap before IR treatment could lead to no discernable 
synergistic responses in A549 or H1650 NSCLC cells.
IR-induced DSB repair is inhibited by ß-lapachone.—Exposure of NQO1+ A549 
cells with ß-lap alone causes specific DNA lesions, including AP sites and DNA single 
strand breaks (18,19) that result in the hyperactivation of PARP activity, noted by a 
significant accumulation of poly(ADP-ribose)-PARP (PAR-PARP) post-translational protein 
modification (Fig. 2A); note that PAR-PARP may represent an inactive form of the enzyme 
(6,10). PARP hyperactivation is strongly induced within 5–10 mins of ß-lap exposure. 
Thereafter, PAR-PARP1 levels were dramatically decreased due to loss of NAD+ levels 
(PARP substrate to produce PAR) (6,7,10) within 20–30 mins during exposure and 
simultaneous removal of PAR moieties from the PARP1 protein by Poly(ADP-ribosyl) 
glycohydrolase (PARG) (Fig. 2A). Interestingly, the activation of ATM (formation of 
pS1981-ATM) and formation of γ-H2AX were significantly delayed in cells exposed to ß-
lap and were not significantly apparent until after PARP hyperactivation was exhausted. 
These data suggest that PARP activity binds and protects AP sites and SSBs, but once PARP 
activity is exhausted cells attempt to either replicate over the damage, or the damage 
becomes hypersensitive to the stress caused by high levels of ß-lap-induced H2O2 (7,10), 
and DSBs are formed. ATM is then activated, which phosphorylates H2AX (γ-H2AX) (Fig. 
2A). While major reductions of NAD+/ATP levels are observed in these cells, there appears 
to be significant levels of nuclear dATP to drive ATM activation and γ-H2AX formation 
over the 2 h time-period (Figs. 2A, B) (17).
We hypothesized that exposure of NQO1+ NSCLC cells to IR + ß-lap resulted in the 
inhibition of DSB repair, due to significant losses of NAD+/ATP resulting from PARP 
hyperactivation and conversion of DNA single strand lesions caused by IR + ß-lap to 
elevated DSBs. A549 cells were exposed to IR (2 Gy) and then treated with a sublethal dose 
of ß-lap, shown to result in significant radiosensitization (Fig. 1B), to monitor DSB repair 
over time using 53BP1 foci formation/nucleus assessments (Figs. 2C–D). Data were then 
graphed showing DSB formation (% nucleus with ≥10 53BP1 foci formation/nucleus) over 
time (Fig. 2D, Supplemental Fig. 1). ß-Lap treatment of IR-exposed A549 cells resulted in 
substantial formation of DSBs per cell nucleus within the two-hour treatment (Figs. 2C–D) 
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followed by a significant inhibition of DSB repair compared to IR-treated or ß-lap-exposed 
cells alone 4 h post-treatment (Supplemental Fig. 1A–B). Approximately less than 10% of 
cells repaired any significant level of DSBs over the 120 mins post-irradiation time when ß-
lap was administered (Figs. 2C, D). In contrast, the significant formation of DSBs noted 
after IR alone were rapidly repaired within 120 mins (Figs. 2C, D). Exposure of A549 cells 
to 3 µM ß-lap only caused a low level of delayed DSB formation at 120 mins, which does 
not lead to a lethal effect with this dose of drug (Fig. 1B). The effects of ß-lap on IR-induced 
DSB repair were reversed by NQO1 inhibition by dicoumarol.
Radiosensitization of subcutaneous NSCLC by ß-lap.—We then established 
subcutaneous xenografts (~400 mm3) using A549 cells in female athymic nude mice and 
treated these mice every other day for 5 injections with: (a) HPßCD vehicle alone (iv); (b) 
IR (2 Gy) alone, only around the xenograft with collimator shielding; (c) ß-lap (20 mg/kg, 
iv) alone; or (d) IR (2 Gy) + 20 mg/kg HPßCD-ß-lap, administered iv immediately after IR 
treatment. Treatment of subcutaneous A549 NSCLC xenografts with ß-lap (20 mg/kg, iv) 
alone is a very ineffective therapeutic regimen, where some growth suppression occurs, but 
regrowth occurs in a rapid manner (Figs. 3A–C) (7). Likewise, IR (2 Gy) alone, given every 
other day for 5 doses had no significant antitumor or long-term survival effects compared to 
vehicle (HPßCD) alone (Figs. 3A–C). In contrast, treatment with IR (2 Gy) + ß-lap (20 
mg/kg, iv) exhibited synergistic antitumor effects, with tumor regression from days 5–16 
compared to vehicle or IR alone and a significant overall apparent cure rate of ~80% of 
exposed mice bearing xenografts. No methemoglobinemia nor normal tissue toxicities were 
noted at 90 days post-treatment and apparently cured mice lived to >300 days post-
treatment. At euthanasia at 350 days, no notable tumor was found within the legs of these IR 
+ ß-lap-treated mice. Pharmacokinetic analyses of mice bearing subcutaneous vs orthotopic 
A549 xenografts grown at the same time in female athymic nude mice revealed that 
subcutaneous xenografts accumulated 8-fold less drug (ß-lap) than in orthotopic A549 
xenografts (Fig. 3D, Supplemental Fig. 2). Levels of ß-lap in A549 tumor, plasma, lung and 
other tissue over time (mins) are represented in Supplemental Fig. 3, where significant levels 
of ß-lap were found in lung tissue and relatively lower levels found in subcutaneous A549 
tumor tissue. The higher levels of the drug in lung tissue, suggested that we examine 
orthotopic NSCLC antitumor and survival effects. Moreover, A549 NSCLC subcutaneous 
tumors (200–400 mm3) show significant synergistic responses to 8 Gy (Supplemental Fig. 
4A) or 10 Gy (Supplemental Fig. 4B) + ß-lap (30 mg/kg, iv) given every other day for 5 
injections, with no significant methemoglobinemia or weight loss (Supplemental Fig. 5).
Radiosensitization of subcutaneous Lewis lung carcinoma (LLC) xenografts 
that express lower levels of NQO1.—LLC cells express significantly less NQO1 
activity (~50 units/mg tissue) compared to A549 NSCLC cells, which express >350 
units/mg tissue (10). LLC levels of NQO1 are still ~5- to 100-fold above normal tissue 
expression of NQO1, with liver tissue NQO1 levels being the highest in these mice at ~10.3 
±0.2 Units/mg tissue. We examined the ability of ß-lap to radiosensitize low NQO1-
expressing LLC xenografts (Fig. 4), exposing 300 mm3 xenografts with varying doses of IR 
(0, 2, 4 8 Gy) alone, varying doses of ß-lap (10 or 20 mg/kg) alone or with 2 Gy IR + 10 or 
20 mg/kg ß-lap given every other day for 5 treatments total (Fig. 4). Minimal antitumor 
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effects were noted with 20 mg/kg ß-lap or IR (2 Gy) alone, or with combination IR (2 Gy) 
+ 10 mg/kg ß-lap. However, exposure of LLC xenograft-bearing athymic mice to IR (2 Gy) 
+ 20 mg/kg ß-lap iv immediately after IR treatment caused a significant increase in survival, 
with ~50% apparent cures at 40 days (Fig. 4). These mice exhibited no weight loss or 
methemolobinemia responses (trouble breathing, lethargy) and remained alive with no 
apparent LLC tumor levels out to 200 days. In addition, necropsy at 200 days showed no 
toxicities to normal tissue nor tumor tissues.
ß-Lapachone radiosensitizes orthotopic NSCLC tumors with low drug levels.
We then examine the ability of ß-lap to radiosensitize orthotopic A549 NSCLCs. A549-luc 
derived cells were used to develop orthotopic A549 NSCLC xenografts in athymic nude 
mice (Fig. 5A), where animal CT scanning of orthotopic tumors were visualized and tumor 
tissue confirmed by immunohistochemical analyses (Fig. 5A). Mice bearing significant 
A549 tumor volumes (Fig. 5A) were treated every other day, for five total doses, with IR (2 
Gy) using collimator-guided irradiations with or without 10, 20 or 30 mg/kg HPßCD-ß-lap 
(iv). Mice were also treated with ß-lap alone at the same doses and frequency. Antitumor 
effects were noted with 20 and 30 mg/kg ß-lap, as well as IR (2 Gy X 5) alone, but 
significant antitumor effects were noted at 40 days post-treatment with IR + 10, 20 or 30 
mg/kg ß-lap (Fig. 5B). ß-lap alone caused significant increases in survival in a dose-
dependent manner, with 10 mg/kg affording little antitumor (Fig. 5B) or overall survival 
advantage. In contrast, 20 and 30 mg/kg ß-lap alone caused dramatic increases in antitumor 
effects (Fig. 5B) and survival advantages, with 35 and 50 day increases in survival at LD50 
levels (Fig. 5C). IR alone caused significant increases in antitumor effects (Fig. 5B) and 
survival (Fig. 5C), but no overall apparent cures in A549-bearing mice. In contrast, a 
significance enhancement of antitumor effects (Fig. 5B) and overall survival (Fig. 5C), 
where 50% (for 10 mg/kg ß-lap) and 60% (for 20 and 30 mg/kg ß-lap) apparent cures were 
noted at 300 days; synergy in terms of overall survival between IR + ß-lap versus IR or ß-lap 
alone was noted as per Chou and Talalay calculations.(28) No overall weight loss or 
methemoglobinemia were noted with any IR alone, ß-lap alone or IR + ß-lap treatments 
(Fig. 5D).
Biomarker analyses reveals DSB repair inhibition from PARP hyperactivation 
in vivo in A549 orthotopic xenografts.—As treated above, athymic nude mice bearing 
A549 orthotopic xenografts were exposed to IR (2 Gy) alone, ß-lap (20 mg/kg, iv) alone or 
to 2 Gy + ß-lap (20 mg/kg iv). Mice (3/group) were then euthanized over time for 
assessment of PAR-PARP levels (Fig. 6A), DSBs via γ-H2AX (Fig. 6B), as well as NAD+ 
and ATP levels (Figs. 6C, D). While ß-lap alone caused significant increases in PAR-PARP 
levels (Fig. 6A), with late forming DSBs (Fig. 6B) and decreases in NAD+ and ATP (Fig. 
6C, D), changes in these same levels in A549 xenografts after IR + ß-lap were dramatically 
greater (Figs. 6A–D). We noted that after IR + ß-lap, PAR-PARP formation occurred early 
within 5–30 mins then decreased by 120 min, while DSB formation increased late between 
30–120 mins. These data are consistent with effects of IR + ß-lap noted in vitro in A549 
culture cells (Figs. 2A–B). In contrast, exposure of tumors with IR (2 Gy) alone resulted in 
no increases in PAR-PARP formation, DSBs (i.e., γ-H2AX (at 30 or 60 mins), or in NAD+ 
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or ATP level losses (Figs. 6A–D). The kinetics of PAR-PARP formation, and NAD+ and 
ATP losses are shown in Supplemental Figs. 6A–C.
DISCUSSION
NQO1 bioctivatable drugs, such as ß-lapachone, are competent tumor-selective agents for 
selective use against cancers that express elevated levels of NQO1, such as found in non-
small cell lung cancers (NSCLC) (10). Here, we demonstrated that the drug is an efficacious 
radiosensitizing agent if added immediately after IR treatment in NQO1+ NSCLC. 
Interestingly, the drug does not work if pretreated prior to IR exposure. It is possible that 
radiation therapy first transiently primes the tumors to facilitate the accumulation and 
delivery of β-lap-HPβCD by modifying the local tumor microenvironment (i.e. vascular 
bursting) as previously reported with other chemical agents (30–32). It is also conceivable 
that IR treatment could induce NQO1 protein expression, and thus increased enzymatic 
activity, to generate more reactive oxygen species with the addition of ß-lap (33). However, 
we have previously reported that the lethal effect of ß-lap (LD50 values) remains relatively 
constant at ≥100 Units of NQO1 activity in multiple cell lines and cancer types (23). These 
possibilities require further optimization and investigation. Mechanistically, we envision that 
the generation of potentially clustered ROS-induced nucleobase damage, DNA single strand 
breaks and extensive apyrimidinic/apurinic (AP) sites by both agents at low doses leads to 
the hyperactivation of PARP, with dramatic losses of NAD+ and ATP. The contribution of 
DSBs by IR treatment, with minimally significant levels induced by ß-lap (Figs. 2C–D, 
Supplemental Fig. 1, Fig. 6B), immediately causes lethal DNA lesions with the combination 
treatments that then may not be repaired efficiently due to the dramatic losses of NAD+ and 
ATP, which are the energetic currency utilized by various DNA damage response and repair 
factors for efficient function (Supplemental Fig. 7). Increased PAR-PARP formation with 
concomitant lowered levels of NAD+ and ATP are consistent with PARP hyperactivation. 
We monitored increased DSB formation through assessment of 53BP1 (Figs. 2C, D, 
Supplemental Fig. 1) and γ-H2AX (Fig. 6B) when IR + ß-lap treatments were given in vitro 
and in vivo, respectively. All of the radiosensitizing effects of ß-lap in NSCLC (Fig. 1C), 
prostate (11) or head and neck (23) cancers were prevented by dicoumarol (DIC), and were 
not seen in NQO1- cancer cells. The net effect of IR + ß-lap is efficacious radiosensitization 
of NQO1+ cancer cells, with minimal effects on methemoglobinemia or normal tissue 
toxicities. The efficacy of IR + ß-lap in preclinical models using NSCLCs (Figs. 3–6) 
against both subcutaneous as well as orthotopic xenografts, warrants a Phase I clinical trial. 
ARQ761 is currently in two phase I clinical trials as a monotherapy against solid cancers, as 
well as used in combination with gemcitabine and Abraxane against pancreatic cancers. 
Therefore, the phase I maximum tolerable dose is already known and will be reported soon.
A major impact of the IR + ß-lap combination therapy is the specificity of the combination 
against specific NQO1 over-expressing cancers. Recently, we reported high levels of NQO1 
expression in a majority of NSCLC (10), pancreatic (18,19), prostate (11), breast (15) and 
head and neck (23) cancers. Interestingly, we also reported that most NSCLC and pancreatic 
cancers that over-expressed NQO1 concomitantly under-express catalase (10) that 
neutralizes H2O2, thus contributing to the efficacy of IR + ß-lap by elevating and prolonging 
H2O2 half-lives and increasing tumor-selective DNA damage needed for PARP 
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hyperactivation and NAD+ degradation. The exhaustion of PARP activity through 
hyperactivation most likely further elevates DSB break formation over time. Thus, we 
anticipate that IR + ß-lap treatments would be an extremely efficacious tumor-selective 
therapy against a wide range of solid cancers. The therapy would allow significant lowering 
of IR and ß-lap doses compared to using either agent alone. The data presented in this study 
reveals a number of novel biomarkers that could be used to examine the efficacy of ß-lap 
(ARQ761 in clinical form) when specifically combined with IR therapies against NSCLC. 
Collectively, our in vitro and in vivo data may provide the impetus needed to (1) translate 
our findings in the clinic; (2) examine other types of tumors that overexpress NQO1 as a 
biomarker for selective and synergistic lethality using our combination therapy; and (3) 
investigate other novel NQO1-bioactivatable drugs in conjunction with ionizing radiation.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Radiosensitization of human NSCLC cells by ß-lapachone.
A. Log-phase A549 NSCLC cells were exposed or not to varying doses of ß-lap for 2 h, with 
or without 50 µM dicoumarol (DIC), a fairly specific inhibitor of NQO1. B. Log-phase 
A549 cells were treated with or without various doses of IR (1–7 Gy) and then immediately 
exposed or not to sublethal (<LD50) doses of ß-lap (1–3 µM, 2h). DIC prevented 
radiosensitization of A549 cells exposed to 2 Gy + 3 µM ß-lap (highest sublethal dose used). 
C. Log-phase H1650 NSCLC cells were exposed or not to IR (2 Gy) and then immediately 
treated or not with varying doses of ß-lap (µM, 2h), with or without 50 µM dicoumarol 
(DIC).
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Figure 2. ß-Lap inhibits DNA double strand break repair.
A. Log-phase A549 NSCLC cells were treated with or without ß-lap (6 µM) and cell extracts 
prepared at various times during treatment to detect PAR-PARP formation, γ-H2AX 
(pS139), pS1981 ATM, total ATM (t-ATM) and α-tubulin steady state levels by Western 
blot. A549 cells were also exposed or not to IR (8 Gy) and analyzed 1 h later. Mock, non-
irradiated cells. DM, media alone. B. Graphical representation of data shown in Fig. 2A. C. 
Representative images of A549 cells exposed or not to IR (2 Gy) alone, ß-lap (3 µM, 2h) 
alone, the combination [IR (2 Gy) + ß-lap (3 µM, 2h), or the combination with DIC (50 µM, 
NQO1 inhibitor) and assessed for DSB breaks over time (0–120 min) using 53BP1 as the 
surrogate marker (in red). Cells were also stained for nuclear DNA using DAPI (in blue). 
Scale bar = 10 µm. D. Graphical representation of data presented in Fig. 2C. ****p<0.0001.
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Figure 3. ß-Lap radiosensitizes subcutaneous A549-luc xenografts in athymic nude mice.
A. Subcutaneous A549-luc xenografts (400 mm3) were generated in athymic nude mice and 
then treated with or without IR (2 Gy) then immediately with or without ß-lap (20 mg/kg) 
for 5 treatments every other day. Representative antitumor responses (at day 20 post-
treatment) are demonstrated for ß-lap alone, IR alone, and the IR + ß-lap combination. B. 
Antitumor responses (tumor volumes, mm3) over time are shown for the treatments 
described in Figs. 3A. C. Overall survival of animals treated as described in Figs. 3A. D. PK 
values for plasma and subcutaneous versus orthotopic A549-luc tumors in athymic nude 
mice. Note the significantly high levels of ß-lap in orthotopic vs subcutaneous A549 tumor 
tissue, whereas plasma levels were identical in both sets of mice. See Supplemental Fig. 2 
for additional PK data.
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Figure 4. ß-Lap radiosensitizes Lewis lung carcinoma (LLC) xenografts in athymic nude mice.
LLC subcutaneous xenografts (300 mm3) were generated in athymic nude mice and treated 
with HPßCD alone, as well as 2, 4, and 8 Gy alone. Mice were also treated with ß-lap (10 or 
20 mg/kg, iv) alone. Finally, mice were also treated with 2 Gy + 10 or 20 mg/kg ß-lap. Mice 
were treated every other day with 2 Gy and then immediately with ß-lap (10 or 20 mg/kg, 
iv). Survival of the treated LLC-bearing mice were then monitored over time (to 40 days). 
N=10 mice/group. ***, p<0.001.
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Figure 5. ß-Lap radiosensitizes orthotopic A549-luc xenografts in athymic nude mice.
A. Imaging of A549-luc mice and IHC analyses of tumor vs associated normal tissue. Top 
left, CT scan of control and A549 tumors. Top right, BLI analyses of a mouse bearing A549-
luc. Bottom left, IHC of tumor (red, arrow) and associated normal tissue (blue). Bottom 
right, extracted A549 tumor. B. Tumor volumes (%T/C) at 20 days post-treatment before and 
after ß-lap alone (10, 20, or 30 mg/kg, iv) without or with IR (2 Gy) pretreatment. Mice 
were treated every other day for 5 treatments and BLI measurements were performed at 10, 
20 30 and 40 days. Shown are results representative of all measurements at 20 days. N=10 
animals/group, ***, p<0.001. C. Overall survival of mice in Fig. 5B *, p<0.5; **, p<0.01; 
p<0.001; ***, p<0.0001; p<0.00001. D. Weight changes monitored for mice treated with or 
without 2 Gy, ß-lap (30 mg/kg, iv) and IR (2 Gy) + ß-lap (30 mg/kg, iv) every other day for 
5 treatments.
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Figure 6. Biomarker analyses after IR + ß-lap indicate increased PAR formation, increased DNA 
double strand breaks (γ−H2AX) with concomitant decreases in NAD+/ATP.
A-D. A549-luc-bearing mice (3/group) were treated as described in Fig. 5B, then sacrificed 
at various times post-treatment. Pooled extracts were then assessed for (A) PAR-PARP 
formation; (B) γ−H2AX; as well as (C) NAD+ and (D) ATP levels. *, p<0.05; **, p<0.01; 
***, p<0.001; and ****, p<0.0001. See Supplemental Fig. 6 for additional data.
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